Inflammatory Bowel Disease

Malik, Talha A.

doi:10.1016/j.suc.2015.07.006

Cited by 158 publications

(81 citation statements)

References 125 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Inflammatory bowel disease (IBD), consisting of Crohn's disease (CD) and ulcerative colitis (UC), results from an uncontrolled immune-mediated inflammatory response to an unknown environmental factor that interacts with the intestinal microbiota in genetically predisposed patients (1) . This leads to symptoms such as diarrhea, abdominal pain in colic and, more rarely, complications such as toxic megacolon (2) .…”

Section: Introductionmentioning

confidence: 99%

Immunization Status of Patients With Inflammatory Bowel Disease

Strasse

Jamur

Marques

et al. 2019

Arq. Gastroenterol.

View full text Add to dashboard Cite

BACKGROUND: Treatment for inflammatory bowel disease (IBD) includes a variety of immunosuppressants and biological agents, which increase the risk of infections due to altered cellular and humoral immunity. Prevention of these infections can be done through vaccination, however, patients with IBD are usually under-immunized. OBJECTIVE: Analyze the immunization status of patients with IBD and confront it with the current recommendations to verify if the immunization guidelines are being followed correctly. METHODS: Analytical cross-sectional study including 239 IBD patients being regularly followed in the Gastroenterology Service from Hospital de Clínicas da Universidade Federal do Paraná, which were subjected to a survey about their relevant demographic data and immunization status. RESULTS: The amount of patients that declared being unaware of their immunization status is high - between 34.3% (Tdap) and 52% (meningococcal) - excepting IIV, hepatitis B and HPV. The vaccines with the largest rates of patients declaring to have taken it are inactivated influenza vaccine (72.4%), BCG (55.3%), hepatitis B (48.3%), measles, mumps and rubella vaccine (43.8%) and DTaP (43%). The vaccines with the lowest rates of patients declaring to have taken it are Haemophilus influenza type b (0.8%), herpes zoster (2.1%) and HPV (3.4%). Patients that are being treated or have been treated with biological therapy have the largest immunization coverage for inactivated influenza vaccine (81%) and PPSV23 (25.9%), also they have the largest awareness rates for those vaccines. CONCLUSION: Although being a specialized service linked to a university hospital, vaccination coverage and patients’ awareness rates proved to be below the desirable level. Vaccination and recovery of the immunization history is recommended immediately after the diagnosis of IBD, regardless of the use of biological agents. Those findings support the need of implementing hospital guidelines and constantly verifying its application by the multidisciplinary team in specialized services in IBD.

show abstract

Section: Introductionmentioning

confidence: 99%

Immunization Status of Patients With Inflammatory Bowel Disease

Strasse

Jamur

Marques

et al. 2019

Arq. Gastroenterol.

View full text Add to dashboard Cite

show abstract

“…Among the GI disorders, inflammatory bowel diseases (IBD), composed of ulcerative colitis (UC) and Crohn's disease (CD), affect 150–250/100,000 people, especially in the USA and Europe, with substantial health care costs of approximately US$6 billion and €4.6–5.6 billion, per year, respectively [2, 3]. …”

Section: Introductionmentioning

confidence: 99%

Colonic and Hepatic Modulation by Lipoic Acid and/or N‐Acetylcysteine Supplementation in Mild Ulcerative Colitis Induced by Dextran Sodium Sulfate in Rats

Moura

Andrade

Araújo³

et al. 2016

Oxidative Medicine and Cellular Longevity

View full text Add to dashboard Cite

Lipoic acid (LA) and N-acetylcysteine (NAC) are antioxidant and anti-inflammatory agents that have not yet been tested on mild ulcerative colitis (UC). This study aims to evaluate the action of LA and/or NAC, on oxidative stress and inflammation markers in colonic and hepatic rat tissues with mild UC, induced by dextran sodium sulfate (DSS) (2% w/v). LA and/or NAC (100 mg·kg·day−1, each) were given, once a day, in the diet, in a pretreatment phase (7 days) and during UC induction (5 days). Colitis induction was confirmed by histological and biochemical analyses (high performance liquid chromatography, spectrophotometry, and Multiplex®). A redox imbalance occurred before an immunological disruption in the colon. NAC led to a decrease in hydrogen peroxide (H2O2), malondialdehyde (MDA) levels, and myeloperoxidase activity. In the liver, DSS did not cause damage but treatments with both antioxidants were potentially harmful, with LA increasing MDA and LA + NAC increasing H2O2, tumor necrosis factor alpha, interferon gamma, and transaminases. In summary, NAC exhibited the highest colonic antioxidant and anti-inflammatory activity, while LA + NAC caused hepatic damage.

show abstract

“…While the incidence has recently been stabilizing in North America and Europe, incidence has been increasing in the Middle East and Asia. New molecular insights are needed to find more effective diagnosis, prognosis[26], and treatments[27]. …”

Section: Colorectal Disease and Rna Sequencingmentioning

confidence: 99%

High throughput RNA sequencing utility for diagnosis and prognosis in colon diseases

Gao

Zhong

Patel

et al. 2017

WJG

View full text Add to dashboard Cite

RNA sequencing is the use of high throughput next generation sequencing technology to survey, characterize, and quantify the transcriptome of a genome. RNA sequencing has been used to analyze the pathogenesis of several malignancies such melanoma, lung cancer, and colorectal cancer. RNA sequencing can identify differential expression of genes (DEG’s), mutated genes, fusion genes, and gene isoforms in disease states. RNA sequencing has been used in the investigation of several colorectal diseases such as colorectal cancer, inflammatory bowel disease (ulcerative colitis and Crohn’s disease), and irritable bowel syndrome.

show abstract

Inflammatory Bowel Disease

Cited by 158 publications

References 125 publications

Immunization Status of Patients With Inflammatory Bowel Disease

Immunization Status of Patients With Inflammatory Bowel Disease

Colonic and Hepatic Modulation by Lipoic Acid and/or N‐Acetylcysteine Supplementation in Mild Ulcerative Colitis Induced by Dextran Sodium Sulfate in Rats

High throughput RNA sequencing utility for diagnosis and prognosis in colon diseases

Contact Info

Product

Resources

About